CU20100027A7 - Composiciones farmacéuticas - Google Patents
Composiciones farmacéuticasInfo
- Publication number
- CU20100027A7 CU20100027A7 CU20100027A CU20100027A CU20100027A7 CU 20100027 A7 CU20100027 A7 CU 20100027A7 CU 20100027 A CU20100027 A CU 20100027A CU 20100027 A CU20100027 A CU 20100027A CU 20100027 A7 CU20100027 A7 CU 20100027A7
- Authority
- CU
- Cuba
- Prior art keywords
- menopause
- breast
- loss
- order
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 2
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 2
- 210000000481 breast Anatomy 0.000 abstract 2
- 230000009245 menopause Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000033830 Hot Flashes Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 206010021639 Incontinence Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010067572 Oestrogenic effect Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010040799 Skin atrophy Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000001548 androgenic effect Effects 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 208000018631 connective tissue disease Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 230000001076 estrogenic effect Effects 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 206010046766 uterine cancer Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen métodos novedosospara el tratamiento o reducción de la probabilidad de adquirir síntomas o enfermedades debido a la menopausia, en mujeres port-menopáusicas, particularmente osteoporosis, atrofia y sequedad vaginal, hipogonadismo, líbido disminuida, atrofia de la piel, enfermedad del tejido conectivo, incontinenciaurinaria, cánceres de mama, del endometrio, ovárico y uterino, sofocos, pérdida de masa muscular, resistencia a la insulina, fatiga, pérdida de enrgía, envejecimiento, síntomas físicos de menopausia, en animales susceptibles de sangre caliente incluyendo humanos, que involucra la administración de un precursor de esteroide de sexo. Dicho método comprende formas novedosas de administración y dosificación de dehidroepiandrosterona (DHEA) con objeto de aprovechar los efectos androgénicos positivos de la lámina propia de las capas vaginales y/o la capa muscular, sin provocar de forma indeseable efectos estrogénicos sistémicos con objeto de evitar el riesgo de cáncer de mama y uterino. Se describen composiciones farmacéuticas para el suministro de ingredientes activos útiles para la invención.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20100027A CU20100027A7 (es) | 2010-02-10 | 2010-02-10 | Composiciones farmacéuticas |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20100027A CU20100027A7 (es) | 2010-02-10 | 2010-02-10 | Composiciones farmacéuticas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20100027A7 true CU20100027A7 (es) | 2011-04-26 |
Family
ID=44303531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20100027A CU20100027A7 (es) | 2010-02-10 | 2010-02-10 | Composiciones farmacéuticas |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU20100027A7 (es) |
-
2010
- 2010-02-10 CU CU20100027A patent/CU20100027A7/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010016A (es) | Composiciones de dhea para el tratamiento de la menopausia | |
| Nappi et al. | Hormonal contraception and bone metabolism: a systematic review | |
| Wharton et al. | Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog) | |
| CU20120175A7 (es) | Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos | |
| JP2017039771A5 (es) | ||
| NI201000184A (es) | Composiciones y métodos para tratar el cáncer del seno. | |
| JP2013500324A5 (es) | ||
| CU20100027A7 (es) | Composiciones farmacéuticas | |
| RU2015126858A (ru) | Применение экстракта пажитника для усиления женского либидо | |
| UA100701C2 (ru) | Композиции dhea для лечения менопаузы | |
| Rãducan et al. | To be or not to be tinea–Misdiagnosis and inappropriate treatment | |
| de Arriba et al. | Cimicifuga racemosa (CR) safety: Pre-and clinical evidence for lack of widespread estrogenic risk | |
| Siegelmann-Danieli et al. | Breast cancer and pregnancy: Critical review of the effects of prior and subsequent pregnancy on the prognosis of young women with breast tumor | |
| XU et al. | Research advances in breast cancer treatment by typical endocrine drugs | |
| Assi | Hand-foot syndrome in an elderly patient: case report | |
| TH801004154A (th) | องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสารตั้งต้นสเทอรอยด์เพศ | |
| MX2016011801A (es) | Crema de estradiol de dosis baja. | |
| Schiavo | Lamivudine/lopinavir/stavudine | |
| Mendieta Eckert | Allergic contact dermatitis in an elderly patient: case report | |
| TH137260A (th) | การรักษาอาการร้อนวูบวาบ, กลุ่มอาการจากการปรับขนาดหลอดเลือด, และอาการเหงื่อท่วมตัวในตอนกลางคืนด้วยสารตั้งต้นของสเตอรอยด์ทางเพศในการรวมกันกับสารปรับคุมเอสโตเจน รีเซปเตอร์อย่างเลือกจำเพาะ | |
| Grossman et al. | Are hormones the answer to low libido? | |
| Abe et al. | 295 Feasibility Examination of Prior Administration of Cyclophosphamide in TC Combination | |
| Shen et al. | 294 Combining Everolimus with a PI3K Inhibitor Mitigate Cross-Talk and Improves Response to Endocrine Therapy in a Pre-Clinical Breast Cancer Model | |
| Han | Cushing syndrome and tinea corporis: case report | |
| Bouchard et al. | Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women |